Regulatory Pathways and Pivotal Trial Characteristics of Medicines Designated under the European Medicines Agency’s Priority Medicines Scheme Approved between 2018 and 2024
- DOI
- 10.1007/s40290-026-00642-w
- Published
- 2026-11-03
- Container
- Pharmaceutical Medicine
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40290-026-00642-w,
title = {Regulatory Pathways and Pivotal Trial Characteristics of Medicines Designated under the European Medicines Agency’s Priority Medicines Scheme Approved between 2018 and 2024},
author = {Vanessa A. Prieto and María Luján Iavecchia and Esther Cucurull and Juan F. Pacheco Páramo},
year = {2026},
journal = {Pharmaceutical Medicine},
doi = {10.1007/s40290-026-00642-w},
url = {https://doi.org/10.1007/s40290-026-00642-w}
}RIS
TY - JOUR TI - Regulatory Pathways and Pivotal Trial Characteristics of Medicines Designated under the European Medicines Agency’s Priority Medicines Scheme Approved between 2018 and 2024 AU - Vanessa A. Prieto AU - María Luján Iavecchia AU - Esther Cucurull AU - Juan F. Pacheco Páramo PY - 2026 JO - Pharmaceutical Medicine DO - 10.1007/s40290-026-00642-w UR - https://doi.org/10.1007/s40290-026-00642-w ER -
APA
Prieto, V. A., Iavecchia, M. L., Cucurull, E., & Páramo, J. F. P. (2026). Regulatory Pathways and Pivotal Trial Characteristics of Medicines Designated under the European Medicines Agency’s Priority Medicines Scheme Approved between 2018 and 2024. Pharmaceutical Medicine. https://doi.org/10.1007/s40290-026-00642-w
Source records
- crossref · retrieved 2026-11-06T04:29:24.823Z